Skip Navigation



Carcinogenesis Advance Access published online on May 16, 2008
Carcinogenesis, doi:10.1093/carcin/bgn117
This Article
Right arrow Advance Access manuscript (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dai, Y.
Right arrow Articles by Faller, D. V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dai, Y.
Right arrow Articles by Faller, D. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2008.

PROHIBITIN AND THE SWI/SNF ATPASE SUBUNIT BRG1 ARE REQUIRED FOR EFFECTIVE ANDROGEN-ANTAGONIST-MEDIATED TRANSCRIPTIONAL REPRESSION OF ANDROGEN RECEPTOR-REGULATED GENES

Yan Dai*, Duyen Ngo, Johanna Jacob, Lora W. Forman and Douglas V. Faller*

Cancer Research Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA

* Address correspondence to: Yan Dai: L913, Cancer Research Center Boston University School of Medicine, Boston, MA 02118 Tel: (617)638-5650. Fax: (617)638-5609. E-mail:yandai{at}bu.edu. Douglas V. Faller: K701, Cancer Center Boston University School of Medicine, Boston, MA 02118 Phone: (617)638-4173. FAX (617)638-4176. E-mail:dfaller{at}bu.edu

Androgen antagonists or androgen deprivation are primary therapeutic modalities for the treatment of prostate cancer. Invariably, however, the disease becomes progressive and unresponsive to androgen ablation therapy (hormone refractory). The molecular mechanisms by which androgen antagonists inhibit prostate cancer proliferation are not fully defined. In this study, we identify two molecules which are required for effective prostate cancer cell responsiveness to androgen antagonists. We establish that androgen receptor (AR)-dependent transcriptional suppression by structurally-distinct androgen antagonists requires the tumor suppressor prohibitin. This requirement for prohibitin was demonstrated using structurally-distinct androgen antagonists, stable and transient knockdown of prohibitin, and transfected and endogenous AR-responsive genes. The SWI/SNF complex core ATPase BRG1, but not its closely-related counterpart ATPase BRM, is required for this repressive action of prohibitin on AR-responsive promoters. Androgen antagonists induce recruitment of prohibitin and BRG1 to endogenous AR-responsive promoters, and induce a physical association between AR and prohibitin and BRG1. The recruitment of prohibitin to endogenous AR-responsive promoters is dependent upon antagonist-bound AR. Prohibitin binding in the PSA promoter results in the recruitment of BRG1 and the dissociation of p300 from the PSA promoter. These findings suggest that prohibitin may function through BRG1-mediated local chromatin remodeling activity and the removal of p300-mediated acetylation to produce androgen antagonist-mediated transcriptional repression. Furthermore, in addition to its necessary role in AR-mediated transcriptional repression, we demonstrate that prohibitin is required for full and efficient androgen antagonist-mediated growth suppression of prostate cancer cells.

Key Words: Androgen Antagonists • Prohibitin • BRG1 • Transcription • Prostate cancer

Received August 25, 2007; revised March 23, 2008; accepted May 6, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.